Lostumbo L, Carbine N, Wallace J, Ezzo J
NBCC, 10615 Great Arbor Dr, Potomac, Maryland, USA, 20854.
Cochrane Database Syst Rev. 2004 Oct 18(4):CD002748. doi: 10.1002/14651858.CD002748.pub2.
Breast cancer is the most common cancer and the second most common cause of cancer-related death among North American and Western European women. Recent progress in understanding the genetic basis of breast cancer, along with rising incidence rates, have resulted in increased interest in prophylactic mastectomy as a method of preventing breast cancer, particularly in those with familial susceptibility.
The primary objective was to determine whether prophylactic mastectomy reduces death from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast. The secondary objective was to examine the effect of prophylactic mastectomy on other endpoints including breast cancer incidence, breast cancer mortality, disease-free survival, physical morbidity, and psychosocial outcomes.
Electronic searches were performed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Cancerlit, and the Science Citation Index.
Inclusion criteria were studies in English of any design type including randomized or nonrandomized controlled trials, cohort studies, case-control studies, and case series with at least ten participants. Participants included women at risk for breast cancer in at least one breast. Interventions included all types of mastectomy performed for the purpose of preventing breast cancer, including subcutaneous mastectomy, total or simple mastectomy, modified radical mastectomy, and radical mastectomy.
Information on patients, interventions, methods, and results were extracted by at least two independent reviewers. Methodological quality was assessed based on how well each study minimized potential selection bias, performance bias, detection bias, and attrition bias. Data for each study were summarized descriptively; quantitative meta-analysis was not feasible due to heterogeneity of study designs and insufficient reporting. Data were analyzed separately for bilateral prophylactic mastectomy (BPM) and contralateral prophylactic mastectomy (CPM).
Twenty-three studies, including more than 4,000 patients, met inclusion criteria. No randomized or nonrandomized controlled trials were found. Most studies were either case series or cohort studies. All studies had methodological limitations, with the most common source of potential bias being systematic differences between the intervention and comparison groups that could potentially be associated with a particular outcome. Thirteen studies assessed the effectiveness of BPM. No study assessed all-cause mortality after BPM. All studies reporting on incidence of breast cancer and disease-specific mortality reported reductions after BPM. Nine studies assessed psychosocial measures; most reported high levels of satisfaction with the decision to have prophylactic mastectomy (PM) but more variable satisfaction with cosmetic results. Only one study assessed satisfaction with the psychological support provided by healthcare personnel during risk counseling and showed that more women were dissatisfied than satisfied with the support they received in the healthcare setting. Worry over breast cancer was significantly reduced after BPM when compared both to baseline worry levels and to the groups who opted for surveillance rather than BPM. Three studies reported body image/feelings of femininity outcomes, and all reported that a substantial minority (about 20%) reported BPM had adverse effects on those domains. Six studies assessed contralateral prophylactic mastectomy. Studies consistently reported reductions in contralateral incidence of breast cancer but were inconsistent about improvements in disease-specific survival. Only one study attempted to control for multiple differences between intervention groups, and this study showed no overall survival advantage for CPM at 15 years. Two case series were exclusively focused on adverse events from prophylactic mastectomy with reconstruction, and both reported rates of unanticipated re-operations from 30% to 49%.
REVIEWERS' CONCLUSIONS: While published observational studies demonstrated that BPM was effective in reducing both the incidence of, and death from, breast cancer, more rigorous prospective studies (ideally randomized trials) are needed. The studies need to be of sufficient duration and make better attempts to control for selection biases to arrive at better estimates of risk reduction. The state of the science is far from exact in predicting who will get or who will die from breast cancer. By one estimate, most of the women deemed high risk by family history (but not necessarily BRCA 1 or 2 mutation carriers) who underwent these procedures would not have died from breast cancer, even without prophylactic surgery. Therefore, women need to understand that this procedure should be considered only among those at very high risk of the disease. For women who had already been diagnosed with a primary tumor, the data were particularly lacking for indications for contralateral prophylactic mastectomy. While it appeared that contralateral mastectomy may reduce the incidence of cancer in the contralateral breast, there was insufficient evidence about whether, and for whom, CPM actually improved survival. Physical morbidity is not uncommon following PM, and many women underwent unanticipated re-operations (usually due to problems with reconstruction); however, these data need to be updated to reflect changes in surgical procedures and reconstruction. Regarding psychosocial outcomes, women generally reported satisfaction with their decisions to have PM but reported satisfaction less consistently for cosmetic outcomes, with diminished satisfaction often due to surgical complications. Therefore, physical morbidity and post-operative surgical complications were areas that should be considered when deciding about PM. With regard to emotional well-being, most women recovered well postoperatively, reporting reduced cancer worry and showing reduced psychological morbidity from their baseline measures; exceptions also have been noted. Of the psychosocial outcomes measured, body image and feelings of femininity were the most adversely affected.
乳腺癌是北美和西欧女性中最常见的癌症,也是癌症相关死亡的第二大常见原因。随着对乳腺癌遗传基础认识的最新进展以及发病率的上升,人们对预防性乳房切除术作为预防乳腺癌的一种方法的兴趣日益增加,尤其是在那些具有家族易感性的人群中。
主要目的是确定预防性乳房切除术是否能降低从未患过乳腺癌的女性以及一侧乳房有乳腺癌病史的女性的全因死亡率。次要目的是研究预防性乳房切除术对其他终点的影响,包括乳腺癌发病率、乳腺癌死亡率、无病生存期、身体发病率和心理社会结局。
在Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE、Cancerlit和科学引文索引中进行了电子检索。
入选标准为任何设计类型的英文研究,包括随机或非随机对照试验、队列研究、病例对照研究以及至少有10名参与者的病例系列。参与者包括至少一侧乳房有患乳腺癌风险的女性。干预措施包括为预防乳腺癌而进行的所有类型的乳房切除术,包括皮下乳房切除术、全乳或单纯乳房切除术、改良根治性乳房切除术和根治性乳房切除术。
至少两名独立的审阅者提取了有关患者、干预措施、方法和结果的信息。根据每项研究将潜在选择偏倚、执行偏倚、检测偏倚和失访偏倚降至最低的程度来评估方法学质量。对每项研究的数据进行了描述性总结;由于研究设计的异质性和报告不足,无法进行定量荟萃分析。分别对双侧预防性乳房切除术(BPM)和对侧预防性乳房切除术(CPM)的数据进行了分析。
23项研究,包括4000多名患者,符合入选标准。未找到随机或非随机对照试验。大多数研究为病例系列或队列研究。所有研究都存在方法学局限性,潜在偏倚的最常见来源是干预组和对照组之间可能与特定结局相关的系统差异。13项研究评估了BPM的有效性。没有研究评估BPM后的全因死亡率。所有报告乳腺癌发病率和疾病特异性死亡率的研究均报告BPM后有所降低。9项研究评估了心理社会指标;大多数报告对进行预防性乳房切除术(PM)的决定满意度较高,但对美容效果的满意度则更为多样。只有一项研究评估了在风险咨询期间医护人员提供的心理支持的满意度,结果显示对在医疗环境中获得的支持不满意的女性多于满意的女性。与基线担忧水平以及选择监测而非BPM的组相比,BPM后对乳腺癌担忧显著降低。3项研究报告了身体形象/女性气质感受结局,所有研究均报告相当一部分少数群体(约20%)称BPM对这些方面有不良影响。6项研究评估了对侧预防性乳房切除术。研究一致报告对侧乳腺癌发病率降低,但在疾病特异性生存率的改善方面并不一致。只有一项研究试图控制干预组之间的多种差异,该研究显示CPM在15年时无总体生存优势。两项病例系列专门关注预防性乳房切除术加重建后的不良事件,两项研究均报告意外再次手术率为30%至49%。
虽然已发表的观察性研究表明BPM在降低乳腺癌发病率和死亡率方面有效,但仍需要更严格的前瞻性研究(理想情况下为随机试验)。这些研究需要有足够的持续时间,并更好地控制选择偏倚,以更准确地估计风险降低情况。在预测谁会患乳腺癌或谁会死于乳腺癌方面,科学现状还远不精确。据估计,大多数因家族病史被视为高危(但不一定是BRCA 1或2突变携带者)而接受这些手术的女性,即使不进行预防性手术,也不会死于乳腺癌。因此,女性需要明白,只有在患该疾病风险非常高的人群中才应考虑这一手术。对于已经被诊断患有原发性肿瘤的女性,关于对侧预防性乳房切除术的指征数据尤其缺乏。虽然对侧乳房切除术似乎可以降低对侧乳腺癌的发病率,但关于CPM是否以及对谁能真正提高生存率的证据不足。PM后身体发病率并不罕见,许多女性接受了意外再次手术(通常是由于重建问题);然而,这些数据需要更新以反映手术程序和重建的变化。关于心理社会结局,女性通常报告对进行PM的决定感到满意,但对美容效果的满意度报告不太一致,满意度降低往往是由于手术并发症。因此,在决定是否进行PM时,应考虑身体发病率和术后手术并发症。关于情绪健康,大多数女性术后恢复良好,报告癌症担忧减少,心理发病率较基线测量有所降低;也有例外情况。在所测量的心理社会结局中,身体形象和女性气质感受受到的不利影响最大。